Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an unconventional approach to metastatic cancer: instead of going after cancer cells ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Michael Kalos, Ph.D., is the founder and managing director of Next Pillar Consulting, where he advises biopharmaceutical and venture organizations. He is also a Venture Partner with Alloy Therapeutics ...
Zacks Investment Research on MSN
MRKR stock up nearly 114% in 3 months: Here's what you need to know
Marker Therapeutics’ MRKR shares have surged approximately 114% over the past three months, driven by strong momentum ...
After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...
MedPage Today on MSN
Autoimmune anemia is the latest condition found responsive to CAR-T therapy
Initial results as promising as those in lupus and other non-cancer diseases driven by B c ...
The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...
Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...
In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback